Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1801)

INSIDE INFORMATION ANNOUNCEMENT
PRODUCT REVENUE IN THE THIRD QUARTER OF 2026

This announcement is made by Innovent Biologics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

In the third quarter of 2026, the Company continued its strong growth momentum, with product revenue exceeding RMB4.7 billion, a year-over-year increase of over 40%. This fully validates the robust momentum and continuous delivery of our "dual-engine" growth strategy. Key products in the general biomedicine franchise, including mazdutide, SINTBILO® (tafolecimab injection) and SYCUME® (teprotumumab N01 injection), continued to expand their market presence rapidly, while multiple tyrosine kinase inhibitor (TKI) products in the oncology franchise achieved strong sales growth, together driving broader-based growth across the Company's commercial portfolio. The synergistic effect of our diverse product matrix continues to drive the optimization of our revenue structure, creating a more enriched and resilient growth engine.

During the year of 2026, the Company has achieved high-quality and rapid growth, further reinforcing its leading position in China's biopharmaceutical industry and highlighting its distinctive value in terms of business visibility and growth potential. Regarding global innovation, the Company is advancing three core assets into global Phase 3 clinical development, while continuing to expand its next-generation pipeline across oncology, cardiovascular and metabolic (CVM) diseases, autoimmune diseases and ophthalmology. Our pipeline currently comprises 41 clinical-stage programs and more than 100 preclinical and early-stage research projects, providing a robust foundation for global innovation and sustainable growth. Meanwhile, the Company has established more than 20 collaboration programs with multinational pharmaceutical companies, including Pfizer, Lilly, Takeda, Roche, of which five are co-development and co-commercialization (Co-Co) programs, further validating the international recognition of the Company's global innovation capabilities.

The Company is at a critical window of its strategic development, committed to transforming from a leading local company into a global premier biopharmaceutical company. Looking toward 2030, the Company has anchored clear core strategic objectives, to achieve total revenue of RMB35 billion to RMB40 billion, benchmark its profit margin to top-tier pharmaceutical companies, advance at least five molecules into global multi-regional Phase 3 development, and achieve product launch in key U.S. and European markets. The Company will continue to advance innovation, globalization and high-quality growth, creating long-term value for patients, shareholders of the Company and society.

The financial information set out in this announcement was prepared based on internal management records of the Group which have not been audited or reviewed by external auditors, and as such, the data is for investors' information only. Such data may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company (including but not limited to those published on an annual or semi-annual basis), due to various uncertainties during the process of collection and collating of such data. This announcement does not constitute, nor should it be construed as, an offer or solicitation for the purchase or sale of any securities or financial instruments of the Group.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China
October 29, 2026

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Ms. Qian Zhang as Executive Director, Mr. Ronald Hao Xi Ede as Non-executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Mr. Shuyun Chen and Dr. Stephen A. Sherwin as Independent Non-executive Directors.